NVTA
Invitae Corporation
Set alert
0.02 0.00 0.00%
0.016 Day range 0.024
52-week range unavailable
- Open
- 0.0172
- Prev close
- 0.019
- Mkt cap
- 5.59M
- Vol
- 22.46M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.016
- High
- 0.024
- Forward P/E
- -0.02
- Beta
- 1.59
- Short ratio
- 7.78
- Inst. own
- 47.39%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 27, 2024
- 50-d avg
- 0.49938
- 200-d avg
- 0.862695
- 1y target
- 0.68
Key statistics
- Market cap
- 5.59M
- Enterprise value
- 1.26B
- Trailing P/E
- 0.00
- Forward P/E
- -0.02
- PEG ratio
- 0.00
- Price / sales
- 0.01
- Price / book
- 0.00
- EPS (TTM)
- -5.36
- Beta
- 1.59
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -299.14%
- Revenue (TTM)
- 481.58M
- Revenue growth
- -9.20%
- Free cash flow
- -34.70M
- Total cash
- 254.57M
- Total debt
- 1.51B
- Return on equity
- 0.00%
- Shares outstanding
- 286.49M
- Short % of float
- 26.20%
- 50-day average
- 0.49938
- 200-day average
- 0.862695
Analyst view
Consensus: hold
Hold
Price target (mean) 0.68 +3478.9% upside
Now 0.019
- Target (low)
- 0.30
- Target (mean)
- 0.68
- Target (high)
- 1.00
Ratings (0m) 5 4 buy · 1 hold · 0 sell
- Strong buy1
- Buy3
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 27, 2024
Expected Feb 27, 2024. Consensus EPS estimate -0.29.
Financials — quick view
NVTA Revenue — quarterly 121.24M
NVTA Net income — quarterly -942.11M
NVTA EPS — quarterly -3.42
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 27, 2024 | Dec 1, 2023 | -0.29 | — | — | — |
| Nov 8, 2023 | Sep 1, 2023 | -0.30 | — | — | — |
| Aug 8, 2023 | Jun 1, 2023 | -0.37 | — | — | — |
| May 9, 2023 | Mar 1, 2023 | -0.41 | — | — | — |
| Feb 28, 2023 | Dec 1, 2022 | -0.55 | — | — | — |
| Nov 8, 2022 | Sep 1, 2022 | -0.59 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2023 | Goldman Sachs | main | Sell | Sell |
| Aug 14, 2023 | Piper Sandler | main | Underweight | Underweight |
| Jul 23, 2023 | Goldman Sachs | main | Sell | Sell |
| Jul 20, 2023 | Goldman Sachs | main | Sell | Sell |
| May 14, 2023 | Raymond James | down | Market Perform | Underperform |
| May 10, 2023 | Goldman Sachs | main | Sell | Sell |
About Invitae Corporation
Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
- Country
- United States
- Website
- invitae.com
News
- Citizen Health Raises $30 Million to Build AI Advocate for Every Patient, Ushering in a New Era of Patient-Centered Healthcare
- Labcorp Finalizes Acquisition of Select Assets of Invitae
- Labcorp Announces 2024 Second Quarter Results
- Invitae Launches Unlock™ Behind the Seizure® Program for Pediatric Epilepsy Patients
- Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln
- Labcorp Announces Winning Bid for Select Assets of Invitae
- Invitae Enters into Agreement with Labcorp for Sale of Business
- Invitae Publishes its Environmental, Social and Governance (ESG) Report
- Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance
- Invitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant Classification
Your note
Sign in to keep a note on NVTA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRIDA THOMAS | General Counsel | Stock Award(Grant) | Oct 17, 2023 | 933,587 |
| GORJANC CHRISTINE MARIE | Director | Stock Award(Grant) | Apr 26, 2023 | 111,022 |
| GUIGLEY ROBERT M | Officer | Stock Award(Grant) | Sep 21, 2023 | 850,000 |
| KNIGHT KENNETH D. | Chief Executive Officer | Sale | May 15, 2023 | 1,671,610 |
| NUSSBAUM ROBERT L. | Officer | Sale | Jun 12, 2023 | 569,345 |
| SCHRANK ANA J. | Chief Financial Officer | Stock Award(Grant) | Oct 1, 2023 | 850,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK Investment Management, LLC | 12.34% | 32,942,606 | 19.94M | Sep 29, 2023 |
| Blackrock Inc. | 7.99% | 21,323,634 | 24.10M | Jun 29, 2023 |
| Nikko Asset Management Americas, Inc. | 6.33% | 16,909,635 | 19.11M | Jun 29, 2023 |
| Sumitomo Mitsui Trust Holdings, Inc. | 6.33% | 16,909,635 | 19.11M | Jun 29, 2023 |
| Vanguard Group Inc | 4.93% | 13,174,436 | 14.89M | Jun 29, 2023 |
| Baker Brothers Advisors, LLC | 3.33% | 8,881,104 | 10.04M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Tr-ARK Innovation ETF | 7.07% | 18,882,867 | 11.43M | Sep 29, 2023 |
| ARK ETF Tr-ARK Genomic Revolution ETF | 3.39% | 9,058,622 | 5.48M | Sep 29, 2023 |
| Vanguard Total Stock Market Index Fund | 2.79% | 7,454,414 | 8.42M | Jun 29, 2023 |
| iShares Russell 2000 ETF | 2.29% | 6,106,491 | 5.64M | Aug 30, 2023 |
| Vanguard Extended Market Index Fund | 1.18% | 3,141,204 | 3.55M | Jun 29, 2023 |
| Fidelity Small Cap Index Fund | 0.88% | 2,349,300 | 3.34M | Jul 30, 2023 |